Therefore, the development of more selective, isoform-specific, non-ATP-competitive inhibitors against IKK family kinases to use in combination therapies and/or as part of a targeted delivery approach is required, particularly in cancers that aberrantly express IKKα protein. Here, CHUK is linked to cancer.